Cyclopropavir

Cyclopropavir (Filociclovir) is an orally active and broad-spectrum anti-herpesvirus compound. Cyclopropavir inhibits UL97 kinase activity. Cyclopropavir has antiviral activity against HCMV, MCMV, and HAdV6 viruses^{[1][2][3][4][5]}. In Vitro:Cyclopropavir exhibits antiviral activity against HCMV in human foreskin fibroblasts (HFFs) and mouse embryo fibroblasts (MEFs)^[1].
Cyclopropavir (15 µM) inhibits UL97 kinase activity in COS7 cells transfected with UL97 and pp65-GFP fusion protein, as shown by increased formation of nuclear aggresomes^[2].
Cyclopropavir (2.5 µM; 5 days) achieves a shorter half-life compared to Ganciclovir (HY-13637) in HCMV-infected human foreskin fibroblasts (HFFs)^[3].
In Vivo:Cyclopropavir (1-10 mg/kg; p.o.; 5-28 days) reduces mortality and viral titers in BALB/c mice and SCID mice infected with MCMV^[4].
Cyclopropavir (10-30 mg/kg; p.o.) prevents mortality, mitigates liver/lung pathology, and reduces viral replication in immunosuppressed Syrian hamsters infected intravenously or intranasally with HAdV6^[5].